Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03821285
Other study ID # 2215CE
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 14, 2019
Est. completion date January 14, 2021

Study information

Verified date January 2019
Source Università degli Studi dell'Insubria
Contact Dina Visca, Dr
Phone +390331829111
Email dina.visca@icsmaugeri.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pulmonary tuberculosis (TB) is an important risk factor for chronic respiratory disease due to residual lung damage. A recent review of the literature on TB sequelae and rehabilitation has provided clear evidence that TB is definitively responsible for lung function impairment. Functional evaluation of TB patients after completion of pulmonary tuberculosis treatment or spontaneous healing should be considered as part of clinical care. Unfortunately, few studies are available in the literature investigating the physiopathology of lung damage, its impact on quality of life, the potential need for pulmonary rehabilitation (PR), and the effects of a PR program.Objectives of this prospective multicentre international study are: Primary Objective-to assess the exercise capacity 6-min walking test in patients with post-TB lung impairment after completion of pulmonary tuberculosis treatment or after spontaneous healing. Secondary Objectives-to assess the effects of the PR program on dyspnoea symptoms and muscle fatigue, quality of life.


Description:

Methods Respiratory functional parameters at baseline and at the end of the 15 sessions rehabilitation programme (RP) will be collected at the participating Centre. Follow-up visit 1 year after completion of RP Baseline assessment

1. After signature of the informed consent to the study, patients will undergo a Pre-screening Visit: data on medical history, current pharmacological therapies, smoking (pack/year), vaccinations, physical examination, vital parameters (blood pressure, heart rate, respiratory rate, oxygen saturation in arterial blood), co-morbidities and Mini Mental State Examination will be collected.

2. Screening Visit (before the RP), during the visit the following data will be collected: number of TB disease episodes, detailed data on the last TB episode (age at onset of TB symptoms, age at TB diagnosis, anti-TB treatment duration, anti-TB drugs administered, socio-economic conditions, education level, physical examination, vital parameters, oxygen saturation in arterial blood, heart rate and respiratory rate). Pulmonary rehabilitation program tailored according to specific patient's needs.

3. Baseline assessment of respiratory function: arterial blood gas (ABG) analysis, spirometry, diffusing capacity of the lungs for carbon monoxide (DLCO), overnight oximetry, electrocardiogram (ECG), chest X-ray (CXR), High-resolution computed tomography (HRCT)

4. Assessment of the rehabilitation programme: functional evaluation (6MWT), muscle strength evaluation (five-repetition sit-to-stand test (5STS)), respiratory muscle strength (maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)), symptoms evaluation (Dyspnea: Medical Research Council Questionnaire (MRC), Modified Borg pre/post 6MWT, Baseline and Transition Dyspnea Indexes (BDI-TDI) and Fatigue: Modified Borg pre/post 6MWT)

5. Assessment of the Quality of Life (QoL): CAT and St George's Respiratory Questionnaire.

Final assessment:

A final assessment will be done at the end of the rehabilitation programme and will include:

c) Only ABG, spirometry and DLCO d) and e).

Pulmonary rehabilitation programme

PR programme will include:

At least 15 aerobic-training sessions by cycle ergometer supervised by a respiratory therapist (5 session per week, 30 minutes each: 5 minutes warm up, 20 minutes training and 5 minutes warm-down) at constant load (calculated with Hill equation, Hill K, et al. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008;89(9):1782-7.) with an adherence of at least 80%.

1. At least 15 strength-training sessions for peripheral muscles (30 minutes calisthenics exercise) with an adherence of at least 80%.

2. At least 3 face to face and/or group educational sessions, for:

- Optimization of inhalation techniques

- Exercise training and maintenance programs

- Daily physical activity

- Airways clearance techniques

- Long oxygen therapy home management.

3. According to individual needs, the PR program should include:

- airways clearance techniques

- inspiratory muscles training (with Threshold®)

Monitoring Anonymous data will be collected in a common electronic format (excel database).

Adverse events (AEs) and severe adverse events (SAEs) will be reported and registered.

Follow-up

Follow-up visit 1 year after completion of RP will include:

c) Only ABG, spirometry, DLCO and overnight oximetry d) and e) Statistical analysis A two-tailed p-value less than 0.05 will be considered statistically significant.

Qualitative and quantitative variables will be described with absolute and relative (percentages) frequencies and means (standard deviations -SD) or medians (interquartile ranges -IQR) depending on their normality, respectively. The mean difference between the two study groups in the 6MWT will be evaluated using the Student's t-test. Differences in the variables associated to the secondary objectives will be evaluated using the Chi-square or Student's t-test for qualitative and quantitative variables. A two-tailed p-value less than 0.05 will be considered statistically significant.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date January 14, 2021
Est. primary completion date July 31, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with post-TB lung impairment after completion of pulmonary tuberculosis treatment - Patients with post- TB impairment after spontaneous healing

Exclusion Criteria:

- Any unstable medical condition

- Musculoskeletal disorders contraindicating participation in the PR program

- Cognitive impairment (Mini Mental State Examination <22)

- Unable to sign informed consent

Study Design


Intervention

Procedure:
Pulmonary Rehabilitation
Pulmonary rehabilitation programme:15 aerobic-training sessions, 15 strength-training sessions for peripheral muscles, 3 face to face and/or Group educational sessions, if needed airways clearance techniques and/or inspiratory muscles training

Locations

Country Name City State
Italy ICS Maugeri, IRCCS Tradate Varese

Sponsors (4)

Lead Sponsor Collaborator
Università degli Studi dell'Insubria Azienda Ospedaliero Universitaria di Sassari, Fondazione Salvatore Maugeri, Instituto Nacional de Enfermedades Respiratorias

Country where clinical trial is conducted

Italy, 

References & Publications (2)

Muñoz-Torrico M, Rendon A, Centis R, D'Ambrosio L, Fuentes Z, Torres-Duque C, Mello F, Dalcolmo M, Pérez-Padilla R, Spanevello A, Migliori GB. Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis? J Bras Pne — View Citation

Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D'Ambrosio L, Migliori GB. New drugs and perspectives for new anti-tuberculosis regimens. Pulmonology. 2018 Mar - Apr;24(2):86-98. doi: 10.1016/j.rppnen.2017.10.009. Epub 2018 Feb 24. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 6-min walking test Exercise capacity 1 year
Secondary dyspnoea Modified BORG scale (0-10) 0 better, 10 worse 1 year
Secondary muscle fatigue Modified Borg scale (0-10) 0 better, 10 worse 1 year
Secondary health related quality of life st. George Respiratory Questionnaire 0 better, 100 worse 1 year
Secondary health status COPD Assessment test-CAT (0-40) 0 better, 40 worse 1 year
See also
  Status Clinical Trial Phase
Completed NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Completed NCT00159341 - Cigarette Smoke Nasal and Whole Blood Challenge in Patients With Chronic Obstructive Pulmonary Disease (COPD) Phase 1
Completed NCT00281203 - Comparison of Alveolar Macrophages in Healthy Individuals Versus Individuals With COPD N/A
Completed NCT00281229 - T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Completed NCT00281216 - Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations N/A
Completed NCT00281190 - Comparison of Alveolar Macrophages in Individuals With COPD Versus Smokers With Normal Pulmonary Function N/A
Completed NCT00281242 - Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease N/A
Completed NCT00069823 - Study of Acid Reflux in Asthma Phase 3
Completed NCT00006513 - Assessing the Occupation Burden in COPD N/A
Completed NCT00006306 - Effects of Chronic Ozone Exposure on Lung Function N/A
Completed NCT00000621 - Feasibility of Retinoic Acid Treatment in Emphysema (FORTE) Phase 2
Completed NCT00000569 - Lung Health Study II Phase 3
Completed NCT00005425 - Statistical Analysis of Vlagtwedde-Vlaardingen Data Set N/A
Completed NCT00005720 - Lay-Led Smoking Cessation Approach for Southeast Asian Men N/A
Completed NCT00000568 - Lung Health Study (LHS) I and III Phase 3
Completed NCT00005281 - Early Risk Predictors For Chronic Pulmonary Disease N/A
Not yet recruiting NCT05286918 - Antibiotic Stewardship in AECOPD Through CRP-Guided Management N/A
Recruiting NCT05565872 - Effects of Supervision During a Community-based Exercise Intervention (Urban Training) in Patients With COPD N/A
Not yet recruiting NCT02928666 - Integration of Guidelines for Comorbidities N/A
Completed NCT02306473 - The Leaky Lung Test Early Phase 1